Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ibudilast (MediciNova, Inc.)
- Development stage
- Unknown
- Lead developer
- MediciNova
- Modality
- Small Molecules
- Administration
- Oral, Ophthalmic
01
Overview
Ibudilast is an orally active, brain-penetrant small molecule that acts as a multi-target phosphodiesterase (PDE) inhibitor and neuroimmune modulator. It selectively inhibits PDE3, PDE4, PDE10, and PDE11, while also acting as an allosteric inhibitor of macrophage migration inhibitory factor (MIF) and an antagonist of Toll-like receptor 4 (TLR4). Originally developed and approved in Japan and South Korea for the treatment of asthma, allergic conjunctivitis, and post-stroke dizziness, ibudilast is being repurposed for neurodegenerative and neuroinflammatory conditions. It crosses the blood-brain barrier to suppress glial cell activation, reduce pro-inflammatory cytokine production, and promote neurotrophic factors. Clinical development is ongoing for amyotrophic lateral sclerosis (ALS), progressive multiple sclerosis (MS), degenerative cervical myelopathy (DCM), glioblastoma, Long COVID, and substance use disorders.
- Brand names
- EyevinalKetasPinatos
- Other names
- ibudilastumneuroimmune medication
02
Targets
CYSLTR1 (Cysteinyl-leukotriene type 1 receptor)MIF (Oxidized macrophage migration inhibitory factor)TLR4 (Toll-like receptor 4)PDE10A (Phosphodiesterase 10A)PDE4APDE4B (3',5'-cyclic-AMP phosphodiesterase 4B)PDE4C (Phosphodiesterase 4C)PDE4D (Phosphodiesterase 4D)PDE3A (Phosphodiesterase 3A)
Beyond the preview
Go deeper on ibudilast (MediciNova, Inc.).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ibudilast (MediciNova, Inc.).